title: Trial of a supplemental dose of four poliovirus vaccines.
abstract: BACKGROUND
  The immunogenicity of oral poliovirus vaccine (OPV), particularly the type 3 component, is lower in infants in most developing countries than in infants in industrialized countries. We conducted a multicenter trial in Oman to evaluate the response to a supplemental dose of four poliovirus vaccine formulations.
  
  
  METHODS
  At nine months of age, infants were randomly assigned to receive inactivated-poliovirus vaccine (IPV), administered subcutaneously; trivalent OPV manufactured in the United States or in Europe; or monovalent type 3 OPV. Serum samples were collected at enrollment and 7 and 30 days later. All of the infants had previously received five doses of OPV.
  
  
  RESULTS
  We enrolled 1025 infants; 785 (76.6 percent) met all the study requirements. At enrollment, 96.8 percent of the infants were seropositive for poliovirus type 1, 98.0 percent for type 2, and 88.0 percent for type 3. At 30 days there were no significant increases in type 3 seroprevalence or in the median antibody titer in the groups of infants who received OPV. Among the recipients of IPV, type 3 seroprevalence increased from 87.8 percent at enrollment to 97.1 percent at 30 days (P<0.001), and the median antibody titer increased from 1:228 to 1:1448 or higher (P<0.001). The rapid initial increase in the antibody titer suggests a secondary immune response.
  
  
  CONCLUSIONS
  A supplemental dose of IPV has excellent immunogenicity and leads to increases in the titer of antibodies against type 3 poliovirus, whereas supplemental doses of the oral vaccines do not have these effects.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. rws4@cdc.gov
authors.forename: R W
authors.initials: RW
authors.lastname: Sutter
authors.forename: A J
authors.initials: AJ
authors.lastname: Suleiman
authors.forename: P
authors.initials: P
authors.lastname: Malankar
authors.forename: S
authors.initials: S
authors.lastname: Al-Khusaiby
authors.forename: F
authors.initials: F
authors.lastname: Mehta
authors.forename: G B
authors.initials: GB
authors.lastname: Clements
authors.forename: M A
authors.initials: MA
authors.lastname: Pallansch
authors.forename: S E
authors.initials: SE
authors.lastname: Robertson
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D003906:Developing Countries; D005243:Feces / Q000821:virology; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D008297:Male; D009850:Oman; D011051:Poliomyelitis / Q000276:immunology* / Q000517:prevention & control; D017955:Poliovirus / Q000145:classification / Q000276:immunology* / Q000302:isolation & purification; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000276:immunology*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000276:immunology*; D016036:Seroepidemiologic Studies
chemical_list: D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral